Results of cebranopadol, a first-in-class, dual NOP/MOP receptor agonist for acute pain after abdominoplasty and bunionectomy

cebranopadol (TRN-228) - Tris Pharma

Todd Bertoch, MD; Megan Shram, PhD; James Hackworth, PhD; Joseph C. Grieco, PhD; Harold Minkowitz, MD

Aug 4, 2026